Your browser doesn't support javascript.
loading
Decision fatigue in low-value prostate cancer screening.
Hunt, Trevor C; Ambrose, Jacob P; Haaland, Benjamin; Kawamoto, Kensaku; Dechet, Christopher B; Lowrance, William T; Hanson, Heidi A; O'Neil, Brock B.
Afiliación
  • Hunt TC; Division of Urology, Department of Surgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
  • Ambrose JP; Population Sciences, Department of Surgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
  • Haaland B; Division of Biostatistics, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah.
  • Kawamoto K; Department of Biomedical Informatics, University of Utah, Salt Lake City, Utah.
  • Dechet CB; Division of Urology, Department of Surgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
  • Lowrance WT; Division of Urology, Department of Surgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
  • Hanson HA; Population Sciences, Department of Surgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
  • O'Neil BB; Division of Urology, Department of Surgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
Cancer ; 127(18): 3343-3353, 2021 09 15.
Article en En | MEDLINE | ID: mdl-34043813
ABSTRACT

BACKGROUND:

Low-value prostate-specific antigen (PSA) testing is common yet contributes substantial waste and downstream patient harm. Decision fatigue may represent an actionable target to reduce low-value urologic care. The objective of this study was to determine whether low-value PSA testing patterns by outpatient clinicians are consistent with decision fatigue.

METHODS:

Outpatient appointments for adult men without prostate cancer were identified at a large academic health system from 2011 through 2018. The authors assessed the association of appointment time with the likelihood of PSA testing, stratified by patient age and appropriateness of testing based on clinical guidelines. Appointments included those scheduled between 800 am and 459 pm, with noon omitted. Urologists were examined separately from other clinicians.

RESULTS:

In 1,581,826 outpatient appointments identified, the median patient age was 54 years (interquartile range, 37-66 years), 1,256,152 participants (79.4%) were White, and 133,693 (8.5%) had family history of prostate cancer. PSA testing would have been appropriate in 36.8% of appointments. Clinicians ordered testing in 3.6% of appropriate appointments and in 1.8% of low-value appointments. Appropriate testing was most likely at 800 am (reference group). PSA testing declined through 1100 am (odds ratio [OR], 0.57; 95% CI, 0.50-0.64) and remained depressed through 400 pm (P < .001). Low-value testing was overall less likely (P < .001) and followed a similar trend, declining steadily from 800 am (OR, 0.48; 95% CI, 0.42-0.56) through 400 pm (P < .001; OR, 0.23; 95% CI, 0.18-0.30). Testing patterns in urologists were noticeably different.

CONCLUSIONS:

Among most clinicians, outpatient PSA testing behaviors appear to be consistent with decision fatigue. These findings establish decision fatigue as a promising, actionable target for reducing wasteful and low-value practices in routine urologic care. LAY

SUMMARY:

Decision fatigue causes poorer choices to be made with repetitive decision making. This study used medical records to investigate whether decision fatigue influenced clinicians' likelihood of ordering a low-value screening test (prostate-specific antigen [PSA]) for prostate cancer. In more than 1.5 million outpatient appointments by adult men without prostate cancer, the chances of both appropriate and low-value PSA testing declined as the clinic day progressed, with a larger decline for appropriate testing. Testing patterns in urologists were different from those reported by other clinicians. The authors conclude that outpatient PSA testing behaviors appear to be consistent with decision fatigue among most clinicians, and interventions may reduce wasteful testing and downstream patient harms.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Antígeno Prostático Específico Tipo de estudio: Diagnostic_studies / Guideline / Prognostic_studies / Screening_studies Límite: Adult / Aged / Humans / Male / Middle aged Idioma: En Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Antígeno Prostático Específico Tipo de estudio: Diagnostic_studies / Guideline / Prognostic_studies / Screening_studies Límite: Adult / Aged / Humans / Male / Middle aged Idioma: En Año: 2021 Tipo del documento: Article